Merck Partners with Hansoh to Enter Oral GLP-1 Obesity Drug Market with $2 Billion Deal
In a strategic move to expand its presence in the obesity treatment market, Merck has formed a partnership with Chinese biotech company Hansoh Pharma to develop an oral GLP-1 receptor agonist pill, known as HS-10535[1][2]. Merck will pay Hansoh $112 million upfront, with additional payments potentially reaching $1.9 billion as specific clinical, regulatory, and commercial milestones are achieved[1]. While Merck will hold rights to develop and commercialize the drug outside China, Hansoh retains the option to co-promote or exclusively commercialize it within China[2]. This deal marks Merck’s first significant venture into obesity therapies and underscores the company's interest in diversifying its pharma portfolio beyond its leading oncology product, Keytruda[1][2].
References
Explore Further
What are the potential benefits and challenges that Merck might face in the development and commercialization of HS-10535 compared to existing obesity treatments by Eli Lilly, Novo Nordisk, and Roche?
How might Hansoh Pharma leverage its retained commercial rights in China to maximize the market success of the oral GLP-1 receptor agonist HS-10535?
In what ways could Merck's shift from focusing on cardiovascular treatments like Januvia to obesity drugs influence its overall business strategy?
What are the key milestones that need to be achieved for Merck to consider the $1.9 billion milestone payments to Hansoh Pharma worthwhile?
How are market analysts predicting the impact of Merck's entrance into the obesity drug market on smaller companies like Viking Therapeutics?